Barrington Research Issues Pessimistic Forecast for DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price

DENTSPLY SIRONA (NASDAQ:XRAY) had its target price dropped by stock analysts at Barrington Research from $15.00 to $13.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research‘s price target indicates a potential upside of 37.86% from the stock’s previous close.

XRAY has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday, August 3rd. Piper Sandler dropped their target price on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Friday, October 9th. Leerink Partners reduced their target price on shares of DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating for the company in a research report on Wednesday, October 14th. Mizuho cut their price target on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday. Finally, BMO Capital Markets cut their price objective on shares of DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating for the company in a research report on Thursday, September 17th. Three equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $12.62.

DENTSPLY SIRONA Stock Performance

Shares of NASDAQ:XRAY opened at $9.43 on Monday. DENTSPLY SIRONA has a 12-month low of $8.32 and a 12-month high of $14.76. The stock has a market cap of $1.88 billion, a PE ratio of -3.43, a P/E/G ratio of 1.20 and a beta of 0.87. The business has a 50 day moving average of $9.87 and a 200-day moving average of $10.94. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.35 by $0.17. The company had revenue of $898.00 million for the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%. The firm’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts forecast that DENTSPLY SIRONA will post 1.39 earnings per share for the current year.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of institutional investors have recently modified their holdings of XRAY. Nykredit A S bought a new position in shares of DENTSPLY SIRONA in the 2nd quarter worth about $38,000. IFP Advisors Inc boosted its position in shares of DENTSPLY SIRONA by 244.4% during the 3rd quarter. IFP Advisors Inc now owns 5,566 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 3,950 shares in the last quarter. Allworth Financial LP bought a new stake in shares of DENTSPLY SIRONA during the 2nd quarter valued at about $51,000. Public Employees Retirement System of Ohio acquired a new stake in DENTSPLY SIRONA during the second quarter worth approximately $69,000. Finally, Citizens Financial Group Inc. RI acquired a new stake in DENTSPLY SIRONA during the second quarter worth approximately $118,000. 95.70% of the stock is owned by institutional investors.

About DENTSPLY SIRONA

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.